Cardea Bio Appoints Experienced Health Technology Executive, Dr. Kelly Huang, as Chief Operating Officer

Paragraf tops ‘Top 10 UK graphene companies’ list
Paragraf™ nominated for Automotive Product of the Year Award

Expanded Leadership Team Supports Continued Operational and Commercial Growth

SAN DIEGO–(BUSINESS WIRE)–Cardea Bio, a Tech+Bio company integrating molecular biology with semiconductor electronics, appoints Kelly Huang, Ph.D. as Chief Operating Officer (COO). Dr. Huang brings more than 25 years of medical device, health IT, and consumer health experience to Cardea.

Spearheading a new class of life science signal detection technology, Cardea’s proprietary Cardean Transistors™ employ graphene to link the digital world of semiconductor microelectronics directly to molecular biology, thereby enabling the development of a new generation of highly sensitive diagnostics, research tools, and other biosensor-integrated applications for a myriad of industries. In this newly created role, Dr. Huang will oversee business operations, including manufacturing and commercial scaling, to meet the needs of Cardea’s growing collection of partners and to reach new markets.

“I am excited to join the preeminent team at Cardea, a disruptive platform company with the talent, technology, and mission to change the future,” says Dr. Huang. “I believe Cardea’s graphene-based, biology-gated transistor technology will solve some of the world’s most pressing problems, and I look forward to working with the team to advance novel innovations into commercial applications.”

Part of Dr. Huang’s responsibilities at Cardea will be to build upon their expansive product portfolio, including their CRISPR-Chip, SNP-Chip, and EV-Chip, as well as chips they’re developing in partnership with biotechnology companies such as Scentian Bio and a number of very large, yet undisclosed, partners.

“Dr. Huang represents the kind of formidable talent, experience, values and diverse set of capabilities we’re investing in for the next stage of Cardea,” states Michael Heltzen, CEO of Cardea Bio. “The hire of Dr. Huang reflects our focus on scaling and commercializing Cardea’s proven applications, in close collaboration with our world-class partners.”

Dr. Huang brings more than twenty-five years of diverse executive and operational experience in medical devices, services, health IT, and consumer health to Cardea. Prior to Cardea, Dr. Huang held the positions of COO and President of Nutri-Therapeutic at L-Nutra, where he supported a significant increase in sales and funding through the COVID-19 pandemic. Before this, he was CEO, President, and Board Director for Obalon Therapeutics, a publicly traded medical device company commercializing novel weight-loss technologies including delivery systems integrating electrical, mechanical, and sensing technologies. Through the previous decade, he held several management and executive roles leading development of multiple new technologies and commercial launches at Nestle Skin Health, Endo Health Solutions, and the Johnson & Johnson family of companies.

This post was originally published at Cardea Bio was acquired by Paragraf on 2 May 2023.

Join our mailing list